Skip to main content
Journal cover image

Comparative effectiveness of surfactant preparations in premature infants.

Publication ,  Journal Article
Trembath, A; Hornik, CP; Clark, R; Smith, PB; Daniels, J; Laughon, M; Best Pharmaceuticals for Children Act—Pediatric Trials Network,
Published in: J Pediatr
October 2013

OBJECTIVE: To compare effectiveness of 3 surfactant preparations (beractant, calfactant, and poractant alfa) in premature infants for preventing 3 outcomes: (1) air leak syndromes; (2) death; and (3) bronchopulmonary dysplasia (BPD) or death (composite outcome). STUDY DESIGN: We conducted a comparative effectiveness study of premature infants admitted to 322 neonatal intensive care units in the US from 2005-2010 who were treated with beractant, calfactant, or poractant alfa. We compared the incidence of air leak syndromes, death, and BPD or death, adjusting for gestational age (GA), antenatal steroids, discharge year, and small for GA status. RESULTS: A total of 51282 infants received surfactant; 40% received beractant, 30% calfactant, and 30% poractant alfa. Median birth weight was 1435 g (IQR 966-2065); median GA was 30 weeks (27-33). On adjusted analysis, we observed a similar risk of air leak syndromes (calfactant vs beractant OR = 1.17 [95% CI: 0.95, 1.43]; calfactant vs poractant OR = 1.23 [0.98, 1.56]; beractant vs poractant OR = 1.06 [0.87, 1.29]), death (calfactant vs beractant OR = 1.14 [0.93, 1.39]; calfactant vs poractant OR = 0.98 [0.78, 1.23]; beractant vs poractant OR = 0.86 [0.72, 1.04]), and BPD or death (calfactant vs beractant OR = 1.08 [0.93, 1.26]; calfactant vs poractant OR = 1.19 [1.00, 1.41]; beractant vs poractant OR = 1.10 [0.96, 1.27]). CONCLUSIONS: Beractant, calfactant, and poractant alfa demonstrated similar effectiveness in prevention of air leak syndromes, death, and BPD or death in premature infants when adjusted for site. Previously described differences in mortality between surfactants likely do not represent true differences in effectiveness but may relate to site variation in outcomes.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Pediatr

DOI

EISSN

1097-6833

Publication Date

October 2013

Volume

163

Issue

4

Start / End Page

955 / 60.e1

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Risk
  • Respiratory Distress Syndrome, Newborn
  • Pulmonary Surfactants
  • Phospholipids
  • Pediatrics
  • Models, Statistical
  • Male
  • Intensive Care, Neonatal
  • Infant, Premature, Diseases
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Trembath, A., Hornik, C. P., Clark, R., Smith, P. B., Daniels, J., Laughon, M., & Best Pharmaceuticals for Children Act—Pediatric Trials Network, . (2013). Comparative effectiveness of surfactant preparations in premature infants. J Pediatr, 163(4), 955-60.e1. https://doi.org/10.1016/j.jpeds.2013.04.053
Trembath, Andrea, Christoph P. Hornik, Reese Clark, P Brian Smith, Julie Daniels, Matthew Laughon, and Matthew Best Pharmaceuticals for Children Act—Pediatric Trials Network. “Comparative effectiveness of surfactant preparations in premature infants.J Pediatr 163, no. 4 (October 2013): 955-60.e1. https://doi.org/10.1016/j.jpeds.2013.04.053.
Trembath A, Hornik CP, Clark R, Smith PB, Daniels J, Laughon M, et al. Comparative effectiveness of surfactant preparations in premature infants. J Pediatr. 2013 Oct;163(4):955-60.e1.
Trembath, Andrea, et al. “Comparative effectiveness of surfactant preparations in premature infants.J Pediatr, vol. 163, no. 4, Oct. 2013, pp. 955-60.e1. Pubmed, doi:10.1016/j.jpeds.2013.04.053.
Trembath A, Hornik CP, Clark R, Smith PB, Daniels J, Laughon M, Best Pharmaceuticals for Children Act—Pediatric Trials Network. Comparative effectiveness of surfactant preparations in premature infants. J Pediatr. 2013 Oct;163(4):955–60.e1.
Journal cover image

Published In

J Pediatr

DOI

EISSN

1097-6833

Publication Date

October 2013

Volume

163

Issue

4

Start / End Page

955 / 60.e1

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Risk
  • Respiratory Distress Syndrome, Newborn
  • Pulmonary Surfactants
  • Phospholipids
  • Pediatrics
  • Models, Statistical
  • Male
  • Intensive Care, Neonatal
  • Infant, Premature, Diseases